Clinical Trial Update: Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting pharmacokinetic evaluation of an 8-week course of inhaled tobramycin for Pseudomonas aeruginosa infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pseudomonas Aeruginosa Infection

Drugs mentioned

• TOBI (Tobramycin inhalation solution)

Snippet

Sponsor: Novartis | Conditions: Pseudomonas Infections | Phase 3 | Status: COMPLETED